cIMPACT-NOW update 3: recommended diagnostic criteria for "Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV" - PubMed (original) (raw)

. 2018 Nov;136(5):805-810.

doi: 10.1007/s00401-018-1913-0. Epub 2018 Sep 26.

Affiliations

cIMPACT-NOW update 3: recommended diagnostic criteria for "Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV"

Daniel J Brat et al. Acta Neuropathol. 2018 Nov.

No abstract available

The IMPACT of Molecular Grading of Gliomas on Contemporary Clinical Practice.
Milano MT, Chan MD, Minniti G, Hattangadi-Gluth JA, Redmond KJ, Soltys SG. Milano MT, et al. Int J Radiat Oncol Biol Phys. 2020 Aug 1;107(5):859-862. doi: 10.1016/j.ijrobp.2020.05.043. Int J Radiat Oncol Biol Phys. 2020. PMID: 32698972 No abstract available.

1. Aibaidula A, Chan AK, Shi Z, Li Y, Zhang R, Yang Ret al (2017) Adult IDH wild-type lower-grade gliomas should be further stratified. Neuro Oncol 19: 1327–1337 Doi 10.1093/neuonc/nox078 -DOI -PMC -PubMed
1. Aoki K, Nakamura H, Suzuki H, Matsuo K, Kataoka K, Shimamura T et al. (2018) Prognostic relevance of genetic alterations in diffuse lower-grade gliomas. Neuro Oncol 20: 66–77 Doi 10.1093/neuonc/nox132 -DOI -PMC -PubMed
1. Arita H, Yamasaki K, Matsushita Y, Nakamura T, Shimokawa A, Takami H et al. (2016) A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas. Acta Neuropathol Commun 4: 79 Doi 10.1186/s40478-016-0351-2 -DOI -PMC -PubMed
1. Cancer Genome Atlas Research N, Brat DJ, Verhaak RG, Aldape KD, Yung WK, Salama SR et al. (2015) Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med 372: 2481–2498 Doi 10.1056/NEJMoa1402121 -DOI -PMC -PubMed
1. Capper D, Jones DTW, Sill M, Hovestadt V, Schrimpf D, Sturm D et al. (2018) DNA methylation-based classification of central nervous system tumours. Nature 555: 469–474 Doi 10.1038/nature26000 -DOI -PMC -PubMed